Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Journal of the American Chemical Society|April 14, 2005
Chemistry of the diazeniumdiolates: Z right harpoon over left harpoon E isomerismYan-Ni Wang, D Scott Bohle, Challice L Bonifant, et al.Cancer Research Communications|August 26, 2024
Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R DomainStamatia C Vorri, Natalie J Holl, Michael Leeming, et al.Journal for Immunotherapy of Cancer|February 6, 2025
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionalityRuyan Rahnama, Monika Kizerwetter, Huilin Yang, et al.Molecular Cancer Therapeutics|April 18, 2003
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activityPaul J Shami, Joseph E Saavedra, Lai Y Wang, et al.Biorxiv : the Preprint Server for Biology|January 3, 2024
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsAdrian C Johnston, Gretchen M Alicea, Cameron C Lee, et al.Nature Reviews. Rheumatology|July 2, 2025
CAR T cell therapy for children with rheumatic disease: the time is nowHolly Wobma, Stacy P Ardoin, Challice L Bonifant, et al.Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.Blood Advances|August 19, 2025
International Consensus Guidelines for the Conduct and Reporting of CAR T-Cell Clinical Trials in AMLSwati Naik, Richard Aplenc, Susanne H C Baumeister, et al.Blood Advances|July 17, 2026
HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALLKevin O McNerney, Soyang Kwon, Swati Naik, et al.Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.Pageof 5